PeptideStack
5.2kquestions
20kanswers
220users

What exactly did the FLOW renal composite measure?

Asked 15 Feb 2026Modified 4 months agoViewed 6.6k times
11

I am reading the trial table rather than the press release, which is why the numbers differ.

I want to understand what this actually establishes, as opposed to what it is being used to imply.

My concern is that I am being invited to draw a conclusion the data does not support.

What is the correct interpretation, and what is the common misreading?

renal-outcomes
renal-outcomes

Kidney endpoints: the FLOW composite, eGFR slope as an endpoint, albuminuria regression, and why an early eGFR dip is expected rather than alarming.

14 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

100 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
shareeditfollowflag
SF
askedshear_at_the_front15k2815 Feb 2026
5Note that the label instructions differ between agents on precisely this point. – lyoph_cake 2 months ago
add a comment

1 Answer

Sorted by votes
47

Start with the population. The inclusion criteria of the trial determine what its result can be extrapolated to, and the extrapolation people want is usually to a population the trial excluded.

Absolute risk reduction, worked: if the control-arm event rate is 8.0 per cent over the follow-up period and the hazard ratio is 0.80, the treated rate is approximately 6.4 per cent, the absolute risk reduction is 1.6 percentage points, and the number needed to treat is 1 ÷ 0.016 ≈ 63 over that period. A 20 per cent relative reduction and a number needed to treat of 63 are the same finding stated two ways, and only one of them sounds impressive.

Relative to absolute, worked

QuantityValueDerivation
Control-arm event rate8.0 %From the trial table, not the abstract
Hazard ratio0.80Reported
Treated event rate6.4 %8.0 × 0.80
Absolute risk reduction1.6 pp8.0 − 6.4
Number needed to treat631 ÷ 0.016
Relative risk reduction20 %1 − 0.80

The last two rows describe the same finding. Only one of them is used in headlines.

The relevant detail is that the rodent thyroid C-cell findings that generated the labelled warning appear to be species-specific: rodent C-cells express GLP-1 receptors at high density, human C-cells at very low density, and human calcitonin data across large trial populations has not reproduced the signal. A family history of medullary thyroid carcinoma or MEN2 is nonetheless a genuine contraindication rather than a theoretical one.

Read the confidence interval, read the estimand, and compute the absolute effect yourself. It takes two minutes and it changes how the result feels.

shareimprove this answerflag
OF
answeredorla_ferriter47k3829 Mar 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.